
Brokerage Barclays starts coverage on genetic testing firm Natera NTRA.O with "overweight" rating and sets PT at $200
PT represents 16.4% upside to stock's last close
Brokerage says NTRA has a "compelling long-term investment" opportunity due to its portfolio diversification in high-growth markets with significant potential for market expansion
Barclays says it is confident the company will continue to report strong results through 2025 driven by sales growth and price increases across its portfolio
NTRA more than tripled in 2024